Agenus (AGEN) Projected to Post Quarterly Earnings on Monday

Agenus (NASDAQ:AGEN - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($1.72) per share and revenue of $26.38 million for the quarter.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.36) by $0.32. The business had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million. On average, analysts expect Agenus to post $-13 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Agenus Stock Performance

Agenus stock traded up $0.25 during trading on Friday, reaching $3.11. 904,613 shares of the company's stock were exchanged, compared to its average volume of 579,368. The firm has a market cap of $78.71 million, a price-to-earnings ratio of -0.28 and a beta of 1.58. Agenus has a 52-week low of $1.38 and a 52-week high of $19.69. The company's 50-day moving average is $2.10 and its two-hundred day moving average is $3.00.

Analyst Upgrades and Downgrades

AGEN has been the subject of several recent analyst reports. B. Riley reissued a "buy" rating on shares of Agenus in a report on Monday, April 21st. StockNews.com raised Agenus from a "sell" rating to a "hold" rating in a research report on Friday, March 21st. Robert W. Baird reduced their price objective on Agenus from $6.00 to $3.00 and set a "neutral" rating for the company in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of Agenus in a report on Wednesday. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $8.75.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.